Introduction
HIV-1 variants belonging to groups O, N and P (HIV-1/non-M), are genetically divergent viruses that are endemic in West Central Africa and are found in other parts of the world as sporadic cases. 1 Group O variants (HIV-1/O, subdivided into two distinct subgroups H and T) 2 are known to harbour a particularly high level of genetic polymorphism which has a negative impact on their natural susceptibility to antiretrovirals, including resistance to all NNRTIs, genotypic resistance to some PIs and diverse phenotypic susceptibility levels to various integrase inhibitors. 1, [3] [4] [5] [6] Temsavir (GSK2616713, formerly BMS-626529) is the active component of the phosphono-oxymethyl prodrug fostemsavir (GSK3684934, formerly BMS-663068), an attachment inhibitor (AI) that inhibits the entry of HIV into CD4! T-lymphocytes by blocking conformational changes in gp120. 7 This mechanism of inhibition is different from that of other entry inhibitors targeting co-receptor binding (maraviroc) or fusion (enfuvirtide). Initial clinical investigations have revealed the safety and efficacy of 8 day monotherapy with fostemsavir in HIV-infected individuals. 8 A Phase IIb study has shown safety, tolerability and equivalent efficacy of a combined ART (cART) including fostemsavir in comparison with a cART including ritonavir-boosted atazanavir in a randomized active-controlled trial.
9,10 Development of fostemsavir is still in progress with an ongoing Phase III study (BRIGHTE, formerly AI438-047) in heavily treatment-experienced HIV-1 infected subjects.
In vitro efficacy of fostemsavir has been investigated using diverse laboratory strains and clinical isolates. 11 The phenotypic susceptibility of 40 HIV-1 subtype B, 48 non-B and HIV-1/O strains revealed that none of the CRF01_AE (n " 8), nor HIV-1/O (n " 2) were susceptible to the drug. The EC 50 values for these strains were .2000 nM, compared with a median EC 50 of 0.65 nM for HIV-1/M.
11
On the other hand, genotypic correlates of decreased susceptibility to fostemsavir have been identified by in vitro selection experiments and clinical study; they corresponded to a set of eight substitutions: L116P, A204D, S375M/H, M426L, M434I, M475I and V506M.
12-14 CRF01_AE subtype-related resistance appears to be associated with the natural presence of substitutions S375H and M475I. 12 This subtype-specific resistance in HIV-1/M, as well as polymorphisms found in other subtypes, highlights the direct impact of genetic diversity on AI efficacy. 11 The phenotypic resistance reported for two HIV-1/O strains has led to the hypothesis that all HIV-1/O might be resistant to fostemsavir. However, the genetic background of these two strains does not fully represent the high intra-group genetic diversity, which can impact drug resistance, as previously described for the Y181C substitution in the reverse transcriptase. 2 The genetic divergence of other non-M variants (N and P) also raises the question of a possible natural resistance to fostemsavir.
Thus, the aim of this work was to investigate the natural genotypic susceptibility of HIV-1 non-M to this new drug, using a large set of representative sequences.
Methods
Analysis was performed on 111 gp120 sequences representative of distinct patients infected with HIV-1/O (n " 100), HIV-1/N (n " 9) and HIV-1/ P (n " 2) (Figure 1 ), that were either downloaded from the Los Alamos National Laboratory (LANL) database (n " 81) (http://www.hiv.lanl.gov/) or obtained from clinical samples (plasma, n " 1; PBMCs, n " 5), or culture cells after co-culture of patients' PBMCs (n " 24), from our laboratory (Supplementary Methods, available as Supplementary data at JAC Online).
The GenBank numbers of the 81 sequences previously described and available in the LANL database are AJ006022, AJ271370, AY532635, DQ017382, GQ324958, GQ324959, GQ324962, JN572926, KY498771, AY16908, KF859742, KF859743, KF859744, KU168286, KU168296, KU168297, KY112585, L20587, AF009033, AY618998, L20571, X96522, AB485667, AF383231, AF383230, AF383232, AF383253, AF383258, AF383257, AF383261, AF383262, AF383237, AF383233, AF383234, AF383235, AF383245, AF383246, AF383248, AF383250, AF383251, AF383252, AF383254, AF383255, AY169812, AF383242, AF383238, AF383236, AF383228, AF383243, AF383229, AF383244, AY169815,  AF383241, AY489910, AY489911, AY489739, AY489917, AY489918,  AY489913, AY489914, AY489912, AY489915, AY489916, AF407418,  X96526, JX245014, JX245015, U82990, U82991, U82992, U82993,  AF383239, AJ302646, AJ302647, AB485668, AF383259, AF383260 , JN571034, KX228804, GU111555 and HQ179987, and the accession number for HXB2 is K03455.
The 111 sequences were aligned to the HIV-1 group M gp120 reference sequence HXB2 (K03455), using MEGA6.0;
15 the presence and frequency of the set of eight substitutions (L116P, A204D, S375M/H, M426L, M434I, M475I and V506M) were investigated.
A phylogenetic analysis of the 111 sequences was performed to ensure the panel was representative of non-M genetic diversity and to eliminate redundant sequences.
Results
A phylogenetic analysis confirmed that the 111 sequences were representative of the current epidemiological intra-group O diversity, with 73 and 27 sequences belonging to subgroups H and T, respectively ( Figure 1 ).
Considering the set of 8 substitutions studied, none of the L116P, A204D or M475I substitutions was observed among the 111 sequences. Instead, WT residues were found at these three positions in both HIV-1/P sequences and in more than 89% of HIV-1/N and HIV-1/O sequences. Other atypical substitutions (L116F/I/S, A204V/S/T), i.e. substitutions found at one of the positions identified, but without currently known impact, were found at frequencies ,4%, mainly in HIV-1/O (Figure 2) . At position 506, a WT or atypical residue was found depending on the non-M group (Figure 2) .
On the other hand, substitutions S375M/H, M426L and M434I were found to be natural polymorphisms at different frequencies according to the variant group. All HIV-1/N sequences (n " 9) harboured the three substitutions S375M, M426L and M434I. Concerning HIV-1/O sequences, 1 HIV-1/O T strain (O.CM.2000.SH0006) harboured the S375H ! M426L combination of substitutions, 10 strains (seven H and three T) presented S375H ! M434I and 95 (69 H, 73%; and 26 T, 27%) had S375H. Moreover, two atypical substitutions, M426S and M434L, were commonly found (90% and 87%, respectively). Finally, only five strains (four H and one T) did not harbour any of these three substitutions, but had atypical residues at these positions (Figure 2) . Altogether, we identified a predominant profile of substitutions combining 116L ! 204A ! 375H ! 426S ! 434L ! 475M ! 506I, found in 67% of the O sequences, this being independent of the H (n " 50; 75%) or T (n " 17; 25%) subgroup. This combination of substitutions was also found in the two HIV-1/P viruses.
Discussion
Fostemsavir is a small molecule belonging to a new class of AIs. Its in vitro efficacy has already been studied for HIV-1/M, highlighting a natural resistance for CRF01_AE strains, 11 and polymorphisms impacting susceptibility for subtypes D, CRF02_AG and CRF30_cpx. 16 Data concerning the divergent non-group M variants are available for only two HIV-1/O strains and showed natural phenotypic resistance with EC 50 .2000 nM. 11 These preliminary results have emphasized the need to explore the possible impact of the wide genetic diversity of non-M HIV-1 divergent strains. Our results showed that non-M viruses possess a group-related natural polymorphism in substitutions identified for variable susceptibility to fostemsavir. HIV-1/N polymorphism presented the M426L substitution, together with the S375M mutation, leading to a genotypic group-related natural resistance to fostemsavir. Indeed, genotypic correlates previously identified M426L as a major substitution associated with resistance, based on the analysis of functional envelope clones from non-responders during 8 day monotherapy with fostemsavir in HIV-infected individuals. 13 Reverse genetic analyses also showed increased phenotypic susceptibility when mutations were returned back to the WT residue. 12, 13 However, a virological response was also observed for two individuals infected with viruses bearing the M426L mutation, suggesting this mutation is not always able to preclude a response. 13 Thus, the combination with the S375M mutation, in 100% of the sequences we analysed, could represent another obstacle for the efficacy of fostemsavir in group N strains. 17 Variable genotypic profiles were found for HIV-1/O. One and ten harboured double pattern substitutions S375H ! M426L and S375H ! M434I, respectively, suggesting natural genotypic resistance. Of note, the latter pattern was found in the BCF03 strain, which was one of the strains found to be phenotypically resistant in a previous study; 11 therefore, our data argue for the role of S375H mutation in genotypic resistance, even in the absence of M426L. This seems consistent with data showing that HIV-1 CRF01_AE subtype viruses are resistant to fostemsavir; indeed, all but two strains (published elsewhere 18 and in 535 sequences from the LANL database, data not shown) harbour the S375H mutation, even if it is often observed in association with the M475I mutation. 11 In addition, the single S375H substitution has been shown to lead to a decrease in susceptibility of .135-fold compared with the WT residue. 12 The other group O strain (BCF01) that was reported to be phenotypically resistant to fostemsavir in the same abovementioned study 13 harbours, in our panel, the predominant profile found in groups O and P, which includes the S375H substitution. This observation argues for the deleterious impact of this substitution; even if the highly frequent association with the atypical residues M426S and M434L in our panel should be explored further to evaluate their precise role. Altogether, our data suggest that three different profiles of mutations could impact the susceptibility of HIV-1/O and HIV-1/P to fostemsavir. Finally, only 5% of the group O strains from our panel had no substitution at the defined positions, suggesting their full susceptibility to inhibition by fostemsavir. Further phenotypic and mutagenesis analyses are now required to confirm the role of atypical residues involved at those positions.
Recently, results from the Phase III BRIGHTE study have shown 54% of responders at week 24; 19 further virological analyses from non-responders will improve knowledge of genotypic resistance profiles for better understanding of the potential susceptibility of non-M variants to fostemsavir.
In conclusion, our study of gp120 genetic polymorphisms supports the hypothesis that HIV-1/non-M viruses could largely be resistant to inhibition by fostemsavir. Associated with the phenotypic resistance data of two HIV-1/O strains, 13 this will likely preclude the use of fostemsavir for people living with HIV-1/O, who already Alessandri-Gradt et al.
have limited therapeutic options. Extensive phenotypic characterization of these non-M viruses warrants further study.
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